- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Pharmaceutical Waste Disposal and Management Market is expected to reach US$ 6,377.95 million by 2030
Jan 10, 2024
Sialorrhea Treatment Market is expected to reach US$ 1,042.37 million by 2030
Dec 12, 2023
Luye Pharma Submits New Drug Application in the U.S. for Its Antidepressant Drug LY03005
Dec 27, 2019
Sarcopenia Treatment Market is expected to reach US$ 5,264.76 million by 2030
Dec 01, 2023
Europe Small Molecule Drug Delivery Market Opportunity Assessment and Forecast up to 2027
Sep 05, 2020
Chronic Cough Market Key Factors and Emerging Opportunities with Current Trends Analysis 2027
Jul 13, 2020
Verde Leaf™ Appoints Carl L. Powell as Chairman
May 05, 2020
Follow us on
